Hyperfine, Inc. filings document a Nasdaq-listed medical device company built around the Swoop® portable MR brain imaging system and related Optive AI™ software. Its Form 8-K reports cover operating results, business updates, preliminary unaudited financial information, investor presentations, and material definitive agreements, including a senior secured term loan facility used for working capital and general corporate purposes.
Proxy materials describe annual meeting matters, governance procedures, and shareholder voting. The filing record also identifies HYPR Class A common stock registered on Nasdaq and provides capital-structure and corporate-governance disclosures tied to commercialization of portable brain MRI.
Hyperfine, Inc. furnished a press release announcing results for the second quarter ended June 30, 2025 and provided a business update; the press release is attached as Exhibit 99.1 to this Form 8-K.
The filing states the furnished material is not deemed filed for purposes of Section 18 of the Exchange Act and is not incorporated by reference. The company lists its Class A common stock (HYPR) on The Nasdaq Stock Market and indicates it is an emerging growth company. The report is signed by Brett Hale in his capacities as Chief Administrative Officer and Chief Financial Officer.
Hyperfine, Inc. (HYPR) received a Nasdaq notice on April 30, 2025 that its closing bid price fell below the $1.00 minimum for 30 consecutive business days and therefore did not meet Nasdaq Listing Rule 5450(a)(1). On August 6, 2025, Nasdaq notified the Company that it has regained compliance with the bid-price requirement and the matter is closed.
Key facts:
- Nasdaq deficiency notice: April 30, 2025
- Regained compliance and matter closed: August 6, 2025
- Ticker: HYPR; security: Class A common stock on the Nasdaq Global Market